The Apt‐Ce6‐PDA@Pt nanoformulation achieves active tumor targeting by specifically recognizing GPC3‐positive cancer cells through the aptamer, whereas PDA facilitates NIR absorption for efficient photothermal conversion. The gene discussed is GPC3; the disease is neoplasm.